nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—ALB—hematologic cancer	0.189	1	CbGaD
Valsartan—CYP2C9—Bexarotene—hematologic cancer	0.0433	0.103	CbGbCtD
Valsartan—SLCO1B1—Irinotecan—hematologic cancer	0.0412	0.0978	CbGbCtD
Valsartan—SLCO1B3—Methotrexate—hematologic cancer	0.0374	0.0888	CbGbCtD
Valsartan—ALB—Imatinib—hematologic cancer	0.0361	0.0857	CbGbCtD
Valsartan—CYP2C9—Idarubicin—hematologic cancer	0.0359	0.0852	CbGbCtD
Valsartan—CYP2C9—Bortezomib—hematologic cancer	0.0266	0.0631	CbGbCtD
Valsartan—ALB—Prednisone—hematologic cancer	0.0238	0.0565	CbGbCtD
Valsartan—CYP2C9—Thalidomide—hematologic cancer	0.0231	0.0549	CbGbCtD
Valsartan—ALB—Irinotecan—hematologic cancer	0.0226	0.0535	CbGbCtD
Valsartan—CYP2C9—Teniposide—hematologic cancer	0.0221	0.0524	CbGbCtD
Valsartan—SLCO1B1—Methotrexate—hematologic cancer	0.0218	0.0517	CbGbCtD
Valsartan—CYP2C9—Ifosfamide—hematologic cancer	0.0204	0.0484	CbGbCtD
Valsartan—CYP2C9—Imatinib—hematologic cancer	0.0195	0.0462	CbGbCtD
Valsartan—CYP2C9—Nilotinib—hematologic cancer	0.0177	0.042	CbGbCtD
Valsartan—ALB—Methotrexate—hematologic cancer	0.0119	0.0283	CbGbCtD
Valsartan—CYP2C9—Cisplatin—hematologic cancer	0.00991	0.0235	CbGbCtD
Valsartan—CYP2C9—Dexamethasone—hematologic cancer	0.00801	0.019	CbGbCtD
Valsartan—Irbesartan—JUN—hematologic cancer	0.00176	0.584	CrCbGaD
Valsartan—Losartan—UGT1A1—hematologic cancer	0.000679	0.226	CrCbGaD
Valsartan—AGTR1—hematopoietic system—hematologic cancer	0.000413	0.138	CbGeAlD
Valsartan—SLCO1B3—lung—hematologic cancer	0.000395	0.132	CbGeAlD
Valsartan—SLCO1B1—hematopoietic system—hematologic cancer	0.000393	0.131	CbGeAlD
Valsartan—AGTR1—blood—hematologic cancer	0.000273	0.0912	CbGeAlD
Valsartan—SLCO1B1—blood—hematologic cancer	0.000261	0.087	CbGeAlD
Valsartan—Candesartan—ABCB1—hematologic cancer	0.000246	0.0819	CrCbGaD
Valsartan—AGTR1—lung—hematologic cancer	0.00024	0.08	CbGeAlD
Valsartan—AGTR1—testis—hematologic cancer	0.000226	0.0755	CbGeAlD
Valsartan—CYP2C9—hematopoietic system—hematologic cancer	0.000199	0.0663	CbGeAlD
Valsartan—ALB—testis—hematologic cancer	0.000174	0.0582	CbGeAlD
Valsartan—Losartan—ALB—hematologic cancer	0.000166	0.0553	CrCbGaD
Valsartan—AGTR1—lymph node—hematologic cancer	0.000164	0.0547	CbGeAlD
Valsartan—Losartan—ABCB1—hematologic cancer	0.000159	0.0528	CrCbGaD
Valsartan—CYP2C9—blood—hematologic cancer	0.000132	0.0439	CbGeAlD
Valsartan—ALB—lymph node—hematologic cancer	0.000126	0.0422	CbGeAlD
Valsartan—Malnutrition—Methotrexate—hematologic cancer	4.54e-05	0.00015	CcSEcCtD
Valsartan—Haemoglobin—Doxorubicin—hematologic cancer	4.54e-05	0.00015	CcSEcCtD
Valsartan—Headache—Gemcitabine—hematologic cancer	4.54e-05	0.00015	CcSEcCtD
Valsartan—Nausea—Vincristine—hematologic cancer	4.54e-05	0.00015	CcSEcCtD
Valsartan—Cardiac disorder—Epirubicin—hematologic cancer	4.53e-05	0.00015	CcSEcCtD
Valsartan—Rhinitis—Doxorubicin—hematologic cancer	4.53e-05	0.00015	CcSEcCtD
Valsartan—Hepatitis—Doxorubicin—hematologic cancer	4.52e-05	0.00015	CcSEcCtD
Valsartan—Haemorrhage—Doxorubicin—hematologic cancer	4.52e-05	0.00015	CcSEcCtD
Valsartan—Hypersensitivity—Prednisolone—hematologic cancer	4.5e-05	0.000149	CcSEcCtD
Valsartan—Pharyngitis—Doxorubicin—hematologic cancer	4.49e-05	0.000148	CcSEcCtD
Valsartan—Dyspepsia—Dexamethasone—hematologic cancer	4.49e-05	0.000148	CcSEcCtD
Valsartan—Dyspepsia—Betamethasone—hematologic cancer	4.49e-05	0.000148	CcSEcCtD
Valsartan—Urinary tract disorder—Doxorubicin—hematologic cancer	4.46e-05	0.000148	CcSEcCtD
Valsartan—Urticaria—Triamcinolone—hematologic cancer	4.46e-05	0.000148	CcSEcCtD
Valsartan—Dysgeusia—Methotrexate—hematologic cancer	4.45e-05	0.000147	CcSEcCtD
Valsartan—Asthenia—Etoposide—hematologic cancer	4.44e-05	0.000147	CcSEcCtD
Valsartan—Connective tissue disorder—Doxorubicin—hematologic cancer	4.44e-05	0.000147	CcSEcCtD
Valsartan—Anaphylactic shock—Prednisone—hematologic cancer	4.44e-05	0.000147	CcSEcCtD
Valsartan—Oedema—Prednisone—hematologic cancer	4.44e-05	0.000147	CcSEcCtD
Valsartan—Angiopathy—Epirubicin—hematologic cancer	4.43e-05	0.000147	CcSEcCtD
Valsartan—Urethral disorder—Doxorubicin—hematologic cancer	4.43e-05	0.000147	CcSEcCtD
Valsartan—Decreased appetite—Dexamethasone—hematologic cancer	4.43e-05	0.000147	CcSEcCtD
Valsartan—Decreased appetite—Betamethasone—hematologic cancer	4.43e-05	0.000147	CcSEcCtD
Valsartan—Nausea—Mitoxantrone—hematologic cancer	4.42e-05	0.000146	CcSEcCtD
Valsartan—Nausea—Irinotecan—hematologic cancer	4.42e-05	0.000146	CcSEcCtD
Valsartan—Immune system disorder—Epirubicin—hematologic cancer	4.41e-05	0.000146	CcSEcCtD
Valsartan—Infection—Prednisone—hematologic cancer	4.41e-05	0.000146	CcSEcCtD
Valsartan—Mediastinal disorder—Epirubicin—hematologic cancer	4.4e-05	0.000146	CcSEcCtD
Valsartan—Gastrointestinal disorder—Dexamethasone—hematologic cancer	4.4e-05	0.000146	CcSEcCtD
Valsartan—Gastrointestinal disorder—Betamethasone—hematologic cancer	4.4e-05	0.000146	CcSEcCtD
Valsartan—Back pain—Methotrexate—hematologic cancer	4.4e-05	0.000145	CcSEcCtD
Valsartan—Fatigue—Betamethasone—hematologic cancer	4.39e-05	0.000145	CcSEcCtD
Valsartan—Fatigue—Dexamethasone—hematologic cancer	4.39e-05	0.000145	CcSEcCtD
Valsartan—Pruritus—Etoposide—hematologic cancer	4.38e-05	0.000145	CcSEcCtD
Valsartan—Shock—Prednisone—hematologic cancer	4.37e-05	0.000144	CcSEcCtD
Valsartan—Nervous system disorder—Prednisone—hematologic cancer	4.35e-05	0.000144	CcSEcCtD
Valsartan—Alopecia—Epirubicin—hematologic cancer	4.32e-05	0.000143	CcSEcCtD
Valsartan—Skin disorder—Prednisone—hematologic cancer	4.31e-05	0.000143	CcSEcCtD
Valsartan—Nausea—Gemcitabine—hematologic cancer	4.31e-05	0.000143	CcSEcCtD
Valsartan—Vomiting—Cisplatin—hematologic cancer	4.3e-05	0.000142	CcSEcCtD
Valsartan—Vision blurred—Methotrexate—hematologic cancer	4.28e-05	0.000142	CcSEcCtD
Valsartan—Mental disorder—Epirubicin—hematologic cancer	4.28e-05	0.000142	CcSEcCtD
Valsartan—Rash—Cisplatin—hematologic cancer	4.26e-05	0.000141	CcSEcCtD
Valsartan—Dermatitis—Cisplatin—hematologic cancer	4.26e-05	0.000141	CcSEcCtD
Valsartan—Malnutrition—Epirubicin—hematologic cancer	4.25e-05	0.000141	CcSEcCtD
Valsartan—Diarrhoea—Etoposide—hematologic cancer	4.24e-05	0.00014	CcSEcCtD
Valsartan—Anorexia—Prednisone—hematologic cancer	4.23e-05	0.00014	CcSEcCtD
Valsartan—Cardiac disorder—Doxorubicin—hematologic cancer	4.2e-05	0.000139	CcSEcCtD
Valsartan—Flatulence—Epirubicin—hematologic cancer	4.19e-05	0.000139	CcSEcCtD
Valsartan—Gastrointestinal pain—Betamethasone—hematologic cancer	4.17e-05	0.000138	CcSEcCtD
Valsartan—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.17e-05	0.000138	CcSEcCtD
Valsartan—Dysgeusia—Epirubicin—hematologic cancer	4.17e-05	0.000138	CcSEcCtD
Valsartan—Hypersensitivity—Triamcinolone—hematologic cancer	4.14e-05	0.000137	CcSEcCtD
Valsartan—Back pain—Epirubicin—hematologic cancer	4.11e-05	0.000136	CcSEcCtD
Valsartan—Angiopathy—Doxorubicin—hematologic cancer	4.1e-05	0.000136	CcSEcCtD
Valsartan—Dizziness—Etoposide—hematologic cancer	4.09e-05	0.000135	CcSEcCtD
Valsartan—Muscle spasms—Epirubicin—hematologic cancer	4.09e-05	0.000135	CcSEcCtD
Valsartan—Immune system disorder—Doxorubicin—hematologic cancer	4.08e-05	0.000135	CcSEcCtD
Valsartan—Vertigo—Methotrexate—hematologic cancer	4.08e-05	0.000135	CcSEcCtD
Valsartan—Mediastinal disorder—Doxorubicin—hematologic cancer	4.07e-05	0.000135	CcSEcCtD
Valsartan—Urticaria—Dexamethasone—hematologic cancer	4.05e-05	0.000134	CcSEcCtD
Valsartan—Urticaria—Betamethasone—hematologic cancer	4.05e-05	0.000134	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Prednisone—hematologic cancer	4.04e-05	0.000134	CcSEcCtD
Valsartan—Dizziness—Prednisolone—hematologic cancer	4.04e-05	0.000134	CcSEcCtD
Valsartan—Asthenia—Triamcinolone—hematologic cancer	4.03e-05	0.000133	CcSEcCtD
Valsartan—Abdominal pain—Dexamethasone—hematologic cancer	4.03e-05	0.000133	CcSEcCtD
Valsartan—Abdominal pain—Betamethasone—hematologic cancer	4.03e-05	0.000133	CcSEcCtD
Valsartan—Nausea—Cisplatin—hematologic cancer	4.02e-05	0.000133	CcSEcCtD
Valsartan—Insomnia—Prednisone—hematologic cancer	4.01e-05	0.000133	CcSEcCtD
Valsartan—Vision blurred—Epirubicin—hematologic cancer	4.01e-05	0.000133	CcSEcCtD
Valsartan—Alopecia—Doxorubicin—hematologic cancer	3.99e-05	0.000132	CcSEcCtD
Valsartan—Paraesthesia—Prednisone—hematologic cancer	3.99e-05	0.000132	CcSEcCtD
Valsartan—Pruritus—Triamcinolone—hematologic cancer	3.97e-05	0.000131	CcSEcCtD
Valsartan—Cough—Methotrexate—hematologic cancer	3.97e-05	0.000131	CcSEcCtD
Valsartan—Mental disorder—Doxorubicin—hematologic cancer	3.96e-05	0.000131	CcSEcCtD
Valsartan—Vomiting—Etoposide—hematologic cancer	3.94e-05	0.00013	CcSEcCtD
Valsartan—Malnutrition—Doxorubicin—hematologic cancer	3.94e-05	0.00013	CcSEcCtD
Valsartan—Dyspepsia—Prednisone—hematologic cancer	3.91e-05	0.000129	CcSEcCtD
Valsartan—Rash—Etoposide—hematologic cancer	3.9e-05	0.000129	CcSEcCtD
Valsartan—Dermatitis—Etoposide—hematologic cancer	3.9e-05	0.000129	CcSEcCtD
Valsartan—Headache—Etoposide—hematologic cancer	3.88e-05	0.000128	CcSEcCtD
Valsartan—Flatulence—Doxorubicin—hematologic cancer	3.88e-05	0.000128	CcSEcCtD
Valsartan—Myalgia—Methotrexate—hematologic cancer	3.87e-05	0.000128	CcSEcCtD
Valsartan—Chest pain—Methotrexate—hematologic cancer	3.87e-05	0.000128	CcSEcCtD
Valsartan—Arthralgia—Methotrexate—hematologic cancer	3.87e-05	0.000128	CcSEcCtD
Valsartan—Decreased appetite—Prednisone—hematologic cancer	3.86e-05	0.000128	CcSEcCtD
Valsartan—Dysgeusia—Doxorubicin—hematologic cancer	3.85e-05	0.000127	CcSEcCtD
Valsartan—Rash—Prednisolone—hematologic cancer	3.85e-05	0.000127	CcSEcCtD
Valsartan—Dermatitis—Prednisolone—hematologic cancer	3.85e-05	0.000127	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.84e-05	0.000127	CcSEcCtD
Valsartan—Fatigue—Prednisone—hematologic cancer	3.83e-05	0.000127	CcSEcCtD
Valsartan—Headache—Prednisolone—hematologic cancer	3.83e-05	0.000127	CcSEcCtD
Valsartan—Vertigo—Epirubicin—hematologic cancer	3.82e-05	0.000126	CcSEcCtD
Valsartan—Syncope—Epirubicin—hematologic cancer	3.81e-05	0.000126	CcSEcCtD
Valsartan—Back pain—Doxorubicin—hematologic cancer	3.81e-05	0.000126	CcSEcCtD
Valsartan—Constipation—Prednisone—hematologic cancer	3.8e-05	0.000126	CcSEcCtD
Valsartan—Muscle spasms—Doxorubicin—hematologic cancer	3.78e-05	0.000125	CcSEcCtD
Valsartan—Palpitations—Epirubicin—hematologic cancer	3.76e-05	0.000124	CcSEcCtD
Valsartan—Loss of consciousness—Epirubicin—hematologic cancer	3.74e-05	0.000124	CcSEcCtD
Valsartan—Dizziness—Triamcinolone—hematologic cancer	3.71e-05	0.000123	CcSEcCtD
Valsartan—Cough—Epirubicin—hematologic cancer	3.71e-05	0.000123	CcSEcCtD
Valsartan—Anaphylactic shock—Methotrexate—hematologic cancer	3.71e-05	0.000123	CcSEcCtD
Valsartan—Vision blurred—Doxorubicin—hematologic cancer	3.71e-05	0.000123	CcSEcCtD
Valsartan—Infection—Methotrexate—hematologic cancer	3.69e-05	0.000122	CcSEcCtD
Valsartan—Nausea—Etoposide—hematologic cancer	3.68e-05	0.000122	CcSEcCtD
Valsartan—Asthenia—Dexamethasone—hematologic cancer	3.66e-05	0.000121	CcSEcCtD
Valsartan—Asthenia—Betamethasone—hematologic cancer	3.66e-05	0.000121	CcSEcCtD
Valsartan—Nervous system disorder—Methotrexate—hematologic cancer	3.64e-05	0.00012	CcSEcCtD
Valsartan—Thrombocytopenia—Methotrexate—hematologic cancer	3.63e-05	0.00012	CcSEcCtD
Valsartan—Gastrointestinal pain—Prednisone—hematologic cancer	3.63e-05	0.00012	CcSEcCtD
Valsartan—Nausea—Prednisolone—hematologic cancer	3.63e-05	0.00012	CcSEcCtD
Valsartan—Myalgia—Epirubicin—hematologic cancer	3.62e-05	0.00012	CcSEcCtD
Valsartan—Chest pain—Epirubicin—hematologic cancer	3.62e-05	0.00012	CcSEcCtD
Valsartan—Arthralgia—Epirubicin—hematologic cancer	3.62e-05	0.00012	CcSEcCtD
Valsartan—Anxiety—Epirubicin—hematologic cancer	3.61e-05	0.000119	CcSEcCtD
Valsartan—Pruritus—Dexamethasone—hematologic cancer	3.61e-05	0.000119	CcSEcCtD
Valsartan—Pruritus—Betamethasone—hematologic cancer	3.61e-05	0.000119	CcSEcCtD
Valsartan—Skin disorder—Methotrexate—hematologic cancer	3.6e-05	0.000119	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.6e-05	0.000119	CcSEcCtD
Valsartan—Vomiting—Triamcinolone—hematologic cancer	3.57e-05	0.000118	CcSEcCtD
Valsartan—Rash—Triamcinolone—hematologic cancer	3.54e-05	0.000117	CcSEcCtD
Valsartan—Dry mouth—Epirubicin—hematologic cancer	3.54e-05	0.000117	CcSEcCtD
Valsartan—Dermatitis—Triamcinolone—hematologic cancer	3.54e-05	0.000117	CcSEcCtD
Valsartan—Vertigo—Doxorubicin—hematologic cancer	3.54e-05	0.000117	CcSEcCtD
Valsartan—Anorexia—Methotrexate—hematologic cancer	3.54e-05	0.000117	CcSEcCtD
Valsartan—Syncope—Doxorubicin—hematologic cancer	3.53e-05	0.000117	CcSEcCtD
Valsartan—Urticaria—Prednisone—hematologic cancer	3.53e-05	0.000117	CcSEcCtD
Valsartan—Headache—Triamcinolone—hematologic cancer	3.52e-05	0.000116	CcSEcCtD
Valsartan—Abdominal pain—Prednisone—hematologic cancer	3.51e-05	0.000116	CcSEcCtD
Valsartan—Diarrhoea—Betamethasone—hematologic cancer	3.49e-05	0.000115	CcSEcCtD
Valsartan—Diarrhoea—Dexamethasone—hematologic cancer	3.49e-05	0.000115	CcSEcCtD
Valsartan—Palpitations—Doxorubicin—hematologic cancer	3.48e-05	0.000115	CcSEcCtD
Valsartan—Anaphylactic shock—Epirubicin—hematologic cancer	3.47e-05	0.000115	CcSEcCtD
Valsartan—Oedema—Epirubicin—hematologic cancer	3.47e-05	0.000115	CcSEcCtD
Valsartan—Hypotension—Methotrexate—hematologic cancer	3.47e-05	0.000115	CcSEcCtD
Valsartan—Loss of consciousness—Doxorubicin—hematologic cancer	3.46e-05	0.000114	CcSEcCtD
Valsartan—Infection—Epirubicin—hematologic cancer	3.45e-05	0.000114	CcSEcCtD
Valsartan—Cough—Doxorubicin—hematologic cancer	3.43e-05	0.000114	CcSEcCtD
Valsartan—Shock—Epirubicin—hematologic cancer	3.42e-05	0.000113	CcSEcCtD
Valsartan—Nervous system disorder—Epirubicin—hematologic cancer	3.4e-05	0.000113	CcSEcCtD
Valsartan—Thrombocytopenia—Epirubicin—hematologic cancer	3.4e-05	0.000112	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.38e-05	0.000112	CcSEcCtD
Valsartan—Skin disorder—Epirubicin—hematologic cancer	3.37e-05	0.000112	CcSEcCtD
Valsartan—Dizziness—Betamethasone—hematologic cancer	3.37e-05	0.000111	CcSEcCtD
Valsartan—Dizziness—Dexamethasone—hematologic cancer	3.37e-05	0.000111	CcSEcCtD
Valsartan—Insomnia—Methotrexate—hematologic cancer	3.35e-05	0.000111	CcSEcCtD
Valsartan—Myalgia—Doxorubicin—hematologic cancer	3.35e-05	0.000111	CcSEcCtD
Valsartan—Arthralgia—Doxorubicin—hematologic cancer	3.35e-05	0.000111	CcSEcCtD
Valsartan—Chest pain—Doxorubicin—hematologic cancer	3.35e-05	0.000111	CcSEcCtD
Valsartan—Anxiety—Doxorubicin—hematologic cancer	3.34e-05	0.00011	CcSEcCtD
Valsartan—Nausea—Triamcinolone—hematologic cancer	3.34e-05	0.00011	CcSEcCtD
Valsartan—Paraesthesia—Methotrexate—hematologic cancer	3.33e-05	0.00011	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.33e-05	0.00011	CcSEcCtD
Valsartan—Anorexia—Epirubicin—hematologic cancer	3.31e-05	0.000109	CcSEcCtD
Valsartan—Dyspnoea—Methotrexate—hematologic cancer	3.31e-05	0.000109	CcSEcCtD
Valsartan—Somnolence—Methotrexate—hematologic cancer	3.3e-05	0.000109	CcSEcCtD
Valsartan—Dry mouth—Doxorubicin—hematologic cancer	3.28e-05	0.000108	CcSEcCtD
Valsartan—Hypersensitivity—Prednisone—hematologic cancer	3.27e-05	0.000108	CcSEcCtD
Valsartan—Dyspepsia—Methotrexate—hematologic cancer	3.27e-05	0.000108	CcSEcCtD
Valsartan—Hypotension—Epirubicin—hematologic cancer	3.24e-05	0.000107	CcSEcCtD
Valsartan—Vomiting—Betamethasone—hematologic cancer	3.24e-05	0.000107	CcSEcCtD
Valsartan—Vomiting—Dexamethasone—hematologic cancer	3.24e-05	0.000107	CcSEcCtD
Valsartan—Decreased appetite—Methotrexate—hematologic cancer	3.22e-05	0.000107	CcSEcCtD
Valsartan—Rash—Dexamethasone—hematologic cancer	3.21e-05	0.000106	CcSEcCtD
Valsartan—Rash—Betamethasone—hematologic cancer	3.21e-05	0.000106	CcSEcCtD
Valsartan—Anaphylactic shock—Doxorubicin—hematologic cancer	3.21e-05	0.000106	CcSEcCtD
Valsartan—Oedema—Doxorubicin—hematologic cancer	3.21e-05	0.000106	CcSEcCtD
Valsartan—Dermatitis—Dexamethasone—hematologic cancer	3.21e-05	0.000106	CcSEcCtD
Valsartan—Dermatitis—Betamethasone—hematologic cancer	3.21e-05	0.000106	CcSEcCtD
Valsartan—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.2e-05	0.000106	CcSEcCtD
Valsartan—Fatigue—Methotrexate—hematologic cancer	3.2e-05	0.000106	CcSEcCtD
Valsartan—Headache—Betamethasone—hematologic cancer	3.19e-05	0.000106	CcSEcCtD
Valsartan—Headache—Dexamethasone—hematologic cancer	3.19e-05	0.000106	CcSEcCtD
Valsartan—Infection—Doxorubicin—hematologic cancer	3.19e-05	0.000106	CcSEcCtD
Valsartan—Asthenia—Prednisone—hematologic cancer	3.18e-05	0.000105	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.16e-05	0.000105	CcSEcCtD
Valsartan—Shock—Doxorubicin—hematologic cancer	3.16e-05	0.000105	CcSEcCtD
Valsartan—Nervous system disorder—Doxorubicin—hematologic cancer	3.15e-05	0.000104	CcSEcCtD
Valsartan—Thrombocytopenia—Doxorubicin—hematologic cancer	3.14e-05	0.000104	CcSEcCtD
Valsartan—Pruritus—Prednisone—hematologic cancer	3.14e-05	0.000104	CcSEcCtD
Valsartan—Insomnia—Epirubicin—hematologic cancer	3.14e-05	0.000104	CcSEcCtD
Valsartan—Skin disorder—Doxorubicin—hematologic cancer	3.12e-05	0.000103	CcSEcCtD
Valsartan—Paraesthesia—Epirubicin—hematologic cancer	3.12e-05	0.000103	CcSEcCtD
Valsartan—Dyspnoea—Epirubicin—hematologic cancer	3.09e-05	0.000102	CcSEcCtD
Valsartan—Somnolence—Epirubicin—hematologic cancer	3.09e-05	0.000102	CcSEcCtD
Valsartan—Anorexia—Doxorubicin—hematologic cancer	3.06e-05	0.000101	CcSEcCtD
Valsartan—Dyspepsia—Epirubicin—hematologic cancer	3.06e-05	0.000101	CcSEcCtD
Valsartan—Diarrhoea—Prednisone—hematologic cancer	3.04e-05	0.0001	CcSEcCtD
Valsartan—Gastrointestinal pain—Methotrexate—hematologic cancer	3.03e-05	0.0001	CcSEcCtD
Valsartan—Nausea—Betamethasone—hematologic cancer	3.03e-05	0.0001	CcSEcCtD
Valsartan—Nausea—Dexamethasone—hematologic cancer	3.03e-05	0.0001	CcSEcCtD
Valsartan—Decreased appetite—Epirubicin—hematologic cancer	3.02e-05	9.98e-05	CcSEcCtD
Valsartan—Hypotension—Doxorubicin—hematologic cancer	3e-05	9.93e-05	CcSEcCtD
Valsartan—Gastrointestinal disorder—Epirubicin—hematologic cancer	3e-05	9.91e-05	CcSEcCtD
Valsartan—Fatigue—Epirubicin—hematologic cancer	2.99e-05	9.9e-05	CcSEcCtD
Valsartan—Constipation—Epirubicin—hematologic cancer	2.97e-05	9.82e-05	CcSEcCtD
Valsartan—Urticaria—Methotrexate—hematologic cancer	2.95e-05	9.75e-05	CcSEcCtD
Valsartan—Dizziness—Prednisone—hematologic cancer	2.93e-05	9.71e-05	CcSEcCtD
Valsartan—Abdominal pain—Methotrexate—hematologic cancer	2.93e-05	9.7e-05	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.93e-05	9.68e-05	CcSEcCtD
Valsartan—Insomnia—Doxorubicin—hematologic cancer	2.9e-05	9.61e-05	CcSEcCtD
Valsartan—Paraesthesia—Doxorubicin—hematologic cancer	2.88e-05	9.54e-05	CcSEcCtD
Valsartan—Dyspnoea—Doxorubicin—hematologic cancer	2.86e-05	9.47e-05	CcSEcCtD
Valsartan—Somnolence—Doxorubicin—hematologic cancer	2.86e-05	9.45e-05	CcSEcCtD
Valsartan—Gastrointestinal pain—Epirubicin—hematologic cancer	2.84e-05	9.39e-05	CcSEcCtD
Valsartan—Dyspepsia—Doxorubicin—hematologic cancer	2.83e-05	9.35e-05	CcSEcCtD
Valsartan—Vomiting—Prednisone—hematologic cancer	2.82e-05	9.34e-05	CcSEcCtD
Valsartan—Rash—Prednisone—hematologic cancer	2.8e-05	9.26e-05	CcSEcCtD
Valsartan—Dermatitis—Prednisone—hematologic cancer	2.8e-05	9.25e-05	CcSEcCtD
Valsartan—Decreased appetite—Doxorubicin—hematologic cancer	2.79e-05	9.24e-05	CcSEcCtD
Valsartan—Headache—Prednisone—hematologic cancer	2.78e-05	9.2e-05	CcSEcCtD
Valsartan—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.77e-05	9.17e-05	CcSEcCtD
Valsartan—Fatigue—Doxorubicin—hematologic cancer	2.77e-05	9.16e-05	CcSEcCtD
Valsartan—Urticaria—Epirubicin—hematologic cancer	2.76e-05	9.12e-05	CcSEcCtD
Valsartan—Constipation—Doxorubicin—hematologic cancer	2.75e-05	9.09e-05	CcSEcCtD
Valsartan—Abdominal pain—Epirubicin—hematologic cancer	2.74e-05	9.08e-05	CcSEcCtD
Valsartan—Hypersensitivity—Methotrexate—hematologic cancer	2.73e-05	9.04e-05	CcSEcCtD
Valsartan—Asthenia—Methotrexate—hematologic cancer	2.66e-05	8.8e-05	CcSEcCtD
Valsartan—Nausea—Prednisone—hematologic cancer	2.64e-05	8.72e-05	CcSEcCtD
Valsartan—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.63e-05	8.69e-05	CcSEcCtD
Valsartan—Pruritus—Methotrexate—hematologic cancer	2.62e-05	8.68e-05	CcSEcCtD
Valsartan—Hypersensitivity—Epirubicin—hematologic cancer	2.56e-05	8.46e-05	CcSEcCtD
Valsartan—Urticaria—Doxorubicin—hematologic cancer	2.55e-05	8.44e-05	CcSEcCtD
Valsartan—Abdominal pain—Doxorubicin—hematologic cancer	2.54e-05	8.4e-05	CcSEcCtD
Valsartan—Diarrhoea—Methotrexate—hematologic cancer	2.54e-05	8.4e-05	CcSEcCtD
Valsartan—Asthenia—Epirubicin—hematologic cancer	2.49e-05	8.24e-05	CcSEcCtD
Valsartan—Pruritus—Epirubicin—hematologic cancer	2.46e-05	8.12e-05	CcSEcCtD
Valsartan—Dizziness—Methotrexate—hematologic cancer	2.45e-05	8.11e-05	CcSEcCtD
Valsartan—Diarrhoea—Epirubicin—hematologic cancer	2.38e-05	7.86e-05	CcSEcCtD
Valsartan—Hypersensitivity—Doxorubicin—hematologic cancer	2.37e-05	7.83e-05	CcSEcCtD
Valsartan—Vomiting—Methotrexate—hematologic cancer	2.36e-05	7.8e-05	CcSEcCtD
Valsartan—Rash—Methotrexate—hematologic cancer	2.34e-05	7.74e-05	CcSEcCtD
Valsartan—Dermatitis—Methotrexate—hematologic cancer	2.34e-05	7.73e-05	CcSEcCtD
Valsartan—Headache—Methotrexate—hematologic cancer	2.32e-05	7.69e-05	CcSEcCtD
Valsartan—Asthenia—Doxorubicin—hematologic cancer	2.3e-05	7.62e-05	CcSEcCtD
Valsartan—Dizziness—Epirubicin—hematologic cancer	2.3e-05	7.59e-05	CcSEcCtD
Valsartan—Pruritus—Doxorubicin—hematologic cancer	2.27e-05	7.52e-05	CcSEcCtD
Valsartan—Vomiting—Epirubicin—hematologic cancer	2.21e-05	7.3e-05	CcSEcCtD
Valsartan—Nausea—Methotrexate—hematologic cancer	2.2e-05	7.29e-05	CcSEcCtD
Valsartan—Diarrhoea—Doxorubicin—hematologic cancer	2.2e-05	7.27e-05	CcSEcCtD
Valsartan—Rash—Epirubicin—hematologic cancer	2.19e-05	7.24e-05	CcSEcCtD
Valsartan—Dermatitis—Epirubicin—hematologic cancer	2.19e-05	7.23e-05	CcSEcCtD
Valsartan—Headache—Epirubicin—hematologic cancer	2.17e-05	7.19e-05	CcSEcCtD
Valsartan—Dizziness—Doxorubicin—hematologic cancer	2.12e-05	7.03e-05	CcSEcCtD
Valsartan—Nausea—Epirubicin—hematologic cancer	2.06e-05	6.82e-05	CcSEcCtD
Valsartan—Vomiting—Doxorubicin—hematologic cancer	2.04e-05	6.76e-05	CcSEcCtD
Valsartan—Rash—Doxorubicin—hematologic cancer	2.03e-05	6.7e-05	CcSEcCtD
Valsartan—Dermatitis—Doxorubicin—hematologic cancer	2.02e-05	6.69e-05	CcSEcCtD
Valsartan—Headache—Doxorubicin—hematologic cancer	2.01e-05	6.66e-05	CcSEcCtD
Valsartan—Nausea—Doxorubicin—hematologic cancer	1.91e-05	6.31e-05	CcSEcCtD
Valsartan—AGTR1—Signaling Pathways—NCOR1—hematologic cancer	1.73e-05	0.000213	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CSF2—hematologic cancer	1.71e-05	0.000211	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FGF1—hematologic cancer	1.71e-05	0.000211	CbGpPWpGaD
Valsartan—ALB—Hemostasis—HGF—hematologic cancer	1.71e-05	0.000211	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CSF2—hematologic cancer	1.69e-05	0.000209	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FOXO1—hematologic cancer	1.69e-05	0.000208	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—IL2—hematologic cancer	1.69e-05	0.000208	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PDGFRB—hematologic cancer	1.69e-05	0.000208	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.68e-05	0.000207	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—ALB—hematologic cancer	1.67e-05	0.000206	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CB—hematologic cancer	1.67e-05	0.000206	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PDGFRA—hematologic cancer	1.66e-05	0.000204	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—JAK1—hematologic cancer	1.65e-05	0.000204	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PRKCG—hematologic cancer	1.65e-05	0.000204	CbGpPWpGaD
Valsartan—ALB—Metabolism—HMMR—hematologic cancer	1.65e-05	0.000204	CbGpPWpGaD
Valsartan—ALB—Metabolism—IDH2—hematologic cancer	1.65e-05	0.000204	CbGpPWpGaD
Valsartan—ALB—Hemostasis—JAK1—hematologic cancer	1.63e-05	0.000201	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PRKCG—hematologic cancer	1.63e-05	0.000201	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MTAP—hematologic cancer	1.63e-05	0.000201	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—MTHFR—hematologic cancer	1.6e-05	0.000197	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NQO1—hematologic cancer	1.59e-05	0.000195	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CD44—hematologic cancer	1.59e-05	0.000195	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	1.56e-05	0.000192	CbGpPWpGaD
Valsartan—ALB—Metabolism—ARNTL—hematologic cancer	1.55e-05	0.000191	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.55e-05	0.000191	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL2RA—hematologic cancer	1.55e-05	0.00019	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL2—hematologic cancer	1.53e-05	0.000189	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TERT—hematologic cancer	1.53e-05	0.000188	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—ABCB1—hematologic cancer	1.53e-05	0.000188	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IL2RA—hematologic cancer	1.53e-05	0.000188	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—SRC—hematologic cancer	1.52e-05	0.000187	CbGpPWpGaD
Valsartan—ALB—Metabolism—CA9—hematologic cancer	1.51e-05	0.000186	CbGpPWpGaD
Valsartan—ALB—Metabolism—ACP5—hematologic cancer	1.51e-05	0.000186	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYCS—hematologic cancer	1.5e-05	0.000185	CbGpPWpGaD
Valsartan—ALB—Metabolism—NCOR2—hematologic cancer	1.49e-05	0.000184	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PDGFB—hematologic cancer	1.49e-05	0.000184	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—HSP90AA1—hematologic cancer	1.49e-05	0.000184	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—VEGFA—hematologic cancer	1.48e-05	0.000182	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PDGFB—hematologic cancer	1.47e-05	0.000181	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TSC2—hematologic cancer	1.46e-05	0.000179	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—FHL2—hematologic cancer	1.46e-05	0.000179	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CDK2—hematologic cancer	1.43e-05	0.000176	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AGRN—hematologic cancer	1.43e-05	0.000176	CbGpPWpGaD
Valsartan—ALB—Metabolism—IDH1—hematologic cancer	1.42e-05	0.000175	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.41e-05	0.000173	CbGpPWpGaD
Valsartan—ALB—Metabolism—ABCC3—hematologic cancer	1.41e-05	0.000173	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTO1—hematologic cancer	1.41e-05	0.000173	CbGpPWpGaD
Valsartan—ALB—Metabolism—TXN—hematologic cancer	1.41e-05	0.000173	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FGFR3—hematologic cancer	1.4e-05	0.000173	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—MAPK3—hematologic cancer	1.4e-05	0.000172	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAPK14—hematologic cancer	1.39e-05	0.000171	CbGpPWpGaD
Valsartan—ALB—Metabolism—SPHK1—hematologic cancer	1.38e-05	0.000169	CbGpPWpGaD
Valsartan—ALB—Hemostasis—MAPK14—hematologic cancer	1.37e-05	0.000169	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ESR1—hematologic cancer	1.36e-05	0.000168	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—TGFB1—hematologic cancer	1.35e-05	0.000167	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HMMR—hematologic cancer	1.35e-05	0.000167	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—IDH2—hematologic cancer	1.35e-05	0.000167	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FN1—hematologic cancer	1.35e-05	0.000166	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CG—hematologic cancer	1.34e-05	0.000165	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.34e-05	0.000165	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NFKBIA—hematologic cancer	1.33e-05	0.000164	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—BAD—hematologic cancer	1.33e-05	0.000164	CbGpPWpGaD
Valsartan—ALB—Hemostasis—FN1—hematologic cancer	1.33e-05	0.000164	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTP1—hematologic cancer	1.32e-05	0.000163	CbGpPWpGaD
Valsartan—ALB—Metabolism—UGT1A1—hematologic cancer	1.32e-05	0.000163	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOTCH1—hematologic cancer	1.32e-05	0.000162	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CD80—hematologic cancer	1.29e-05	0.000159	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CG—hematologic cancer	1.29e-05	0.000159	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KIT—hematologic cancer	1.29e-05	0.000159	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—NRAS—hematologic cancer	1.29e-05	0.000159	CbGpPWpGaD
Valsartan—ALB—Metabolism—CRABP1—hematologic cancer	1.29e-05	0.000158	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC22A1—hematologic cancer	1.29e-05	0.000158	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.28e-05	0.000158	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	1.28e-05	0.000157	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ARNTL—hematologic cancer	1.27e-05	0.000157	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CG—hematologic cancer	1.27e-05	0.000157	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTPN11—hematologic cancer	1.26e-05	0.000156	CbGpPWpGaD
Valsartan—ALB—Metabolism—ALOX5—hematologic cancer	1.25e-05	0.000154	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ABCB1—hematologic cancer	1.25e-05	0.000154	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PTPN11—hematologic cancer	1.25e-05	0.000154	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CREBBP—hematologic cancer	1.25e-05	0.000153	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ACP5—hematologic cancer	1.24e-05	0.000152	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CA9—hematologic cancer	1.24e-05	0.000152	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—MAPK3—hematologic cancer	1.23e-05	0.000152	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CREB1—hematologic cancer	1.23e-05	0.000151	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NCOR2—hematologic cancer	1.22e-05	0.00015	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NCOR1—hematologic cancer	1.22e-05	0.00015	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTM1—hematologic cancer	1.22e-05	0.00015	CbGpPWpGaD
Valsartan—ALB—Metabolism—NUP98—hematologic cancer	1.21e-05	0.000149	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—BRAF—hematologic cancer	1.21e-05	0.000149	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL2—hematologic cancer	1.2e-05	0.000148	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6R—hematologic cancer	1.2e-05	0.000147	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CREBBP—hematologic cancer	1.19e-05	0.000147	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CD—hematologic cancer	1.18e-05	0.000145	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CREBBP—hematologic cancer	1.18e-05	0.000145	CbGpPWpGaD
Valsartan—ALB—Metabolism—NCOA3—hematologic cancer	1.18e-05	0.000145	CbGpPWpGaD
Valsartan—ALB—Metabolism—ADCY7—hematologic cancer	1.18e-05	0.000145	CbGpPWpGaD
Valsartan—ALB—Metabolism—NUP214—hematologic cancer	1.17e-05	0.000144	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALB—hematologic cancer	1.17e-05	0.000144	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—IDH1—hematologic cancer	1.16e-05	0.000143	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	1.16e-05	0.000143	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CA—hematologic cancer	1.15e-05	0.000142	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTO1—hematologic cancer	1.15e-05	0.000142	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TXN—hematologic cancer	1.15e-05	0.000142	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCC3—hematologic cancer	1.15e-05	0.000142	CbGpPWpGaD
Valsartan—ALB—Metabolism—ABCG2—hematologic cancer	1.15e-05	0.000141	CbGpPWpGaD
Valsartan—ALB—Metabolism—MTR—hematologic cancer	1.15e-05	0.000141	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAP2K1—hematologic cancer	1.14e-05	0.00014	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CD—hematologic cancer	1.13e-05	0.000139	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SPHK1—hematologic cancer	1.13e-05	0.000139	CbGpPWpGaD
Valsartan—ALB—Metabolism—ENO2—hematologic cancer	1.12e-05	0.000138	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CA—hematologic cancer	1.12e-05	0.000138	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CD—hematologic cancer	1.12e-05	0.000138	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3R1—hematologic cancer	1.12e-05	0.000137	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—KRAS—hematologic cancer	1.11e-05	0.000136	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTT1—hematologic cancer	1.09e-05	0.000134	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FGF2—hematologic cancer	1.08e-05	0.000133	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—UGT1A1—hematologic cancer	1.08e-05	0.000133	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—MTHFR—hematologic cancer	1.07e-05	0.000132	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.07e-05	0.000132	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3R1—hematologic cancer	1.07e-05	0.000132	CbGpPWpGaD
Valsartan—ALB—Metabolism—SDC1—hematologic cancer	1.07e-05	0.000131	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3R1—hematologic cancer	1.06e-05	0.00013	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC22A1—hematologic cancer	1.05e-05	0.00013	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CRABP1—hematologic cancer	1.05e-05	0.00013	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—JAK2—hematologic cancer	1.04e-05	0.000128	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CB—hematologic cancer	1.03e-05	0.000127	CbGpPWpGaD
Valsartan—ALB—Hemostasis—JAK2—hematologic cancer	1.03e-05	0.000126	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALOX5—hematologic cancer	1.03e-05	0.000126	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—CREBBP—hematologic cancer	1.02e-05	0.000126	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.02e-05	0.000125	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CA—hematologic cancer	1.02e-05	0.000125	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MDM2—hematologic cancer	1.01e-05	0.000125	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NUP98—hematologic cancer	9.93e-06	0.000122	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CB—hematologic cancer	9.86e-06	0.000121	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MTOR—hematologic cancer	9.86e-06	0.000121	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CB—hematologic cancer	9.75e-06	0.00012	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ADCY7—hematologic cancer	9.64e-06	0.000119	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NCOA3—hematologic cancer	9.64e-06	0.000119	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	9.61e-06	0.000118	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NUP214—hematologic cancer	9.58e-06	0.000118	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	9.48e-06	0.000117	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	9.47e-06	0.000117	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—HRAS—hematologic cancer	9.42e-06	0.000116	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—AKT1—hematologic cancer	9.42e-06	0.000116	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MTR—hematologic cancer	9.38e-06	0.000116	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCG2—hematologic cancer	9.38e-06	0.000116	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDKN1B—hematologic cancer	9.26e-06	0.000114	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ENO2—hematologic cancer	9.2e-06	0.000113	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AKT1—hematologic cancer	9.16e-06	0.000113	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CASP3—hematologic cancer	9.07e-06	0.000112	CbGpPWpGaD
Valsartan—ALB—Metabolism—CD44—hematologic cancer	9.06e-06	0.000112	CbGpPWpGaD
Valsartan—ALB—Metabolism—NQO1—hematologic cancer	9.06e-06	0.000112	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL2—hematologic cancer	9.06e-06	0.000112	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CG—hematologic cancer	9.03e-06	0.000111	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6—hematologic cancer	9.01e-06	0.000111	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IL2—hematologic cancer	8.95e-06	0.00011	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTT1—hematologic cancer	8.92e-06	0.00011	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTEN—hematologic cancer	8.89e-06	0.00011	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	8.87e-06	0.000109	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCND1—hematologic cancer	8.83e-06	0.000109	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—JUN—hematologic cancer	8.81e-06	0.000109	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	8.79e-06	0.000108	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SDC1—hematologic cancer	8.72e-06	0.000107	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYCS—hematologic cancer	8.57e-06	0.000106	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDKN1A—hematologic cancer	8.54e-06	0.000105	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTEN—hematologic cancer	8.52e-06	0.000105	CbGpPWpGaD
Valsartan—ALB—Metabolism—HSP90AA1—hematologic cancer	8.52e-06	0.000105	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—EP300—hematologic cancer	8.48e-06	0.000104	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CREBBP—hematologic cancer	8.37e-06	0.000103	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAPK8—hematologic cancer	8.34e-06	0.000103	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	8.33e-06	0.000103	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AKT1—hematologic cancer	8.32e-06	0.000102	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	8.22e-06	0.000101	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EP300—hematologic cancer	8.13e-06	0.0001	CbGpPWpGaD
Valsartan—ALB—Hemostasis—EP300—hematologic cancer	8.03e-06	9.89e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CD—hematologic cancer	7.93e-06	9.77e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SRC—hematologic cancer	7.9e-06	9.73e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	7.87e-06	9.69e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALB—hematologic cancer	7.83e-06	9.64e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SRC—hematologic cancer	7.81e-06	9.62e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—VEGFA—hematologic cancer	7.7e-06	9.48e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	7.67e-06	9.44e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—STAT3—hematologic cancer	7.62e-06	9.39e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—VEGFA—hematologic cancer	7.61e-06	9.37e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NRAS—hematologic cancer	7.6e-06	9.36e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTP1—hematologic cancer	7.56e-06	9.31e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NRAS—hematologic cancer	7.51e-06	9.25e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3R1—hematologic cancer	7.49e-06	9.23e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CD44—hematologic cancer	7.42e-06	9.13e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NQO1—hematologic cancer	7.42e-06	9.13e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	7.31e-06	9e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAPK3—hematologic cancer	7.28e-06	8.97e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	7.26e-06	8.94e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—MAPK3—hematologic cancer	7.2e-06	8.86e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—ABCB1—hematologic cancer	7.15e-06	8.81e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MYC—hematologic cancer	7.08e-06	8.72e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TGFB1—hematologic cancer	7.07e-06	8.7e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYCS—hematologic cancer	7.02e-06	8.64e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TGFB1—hematologic cancer	6.98e-06	8.6e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	6.97e-06	8.59e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—NCOR1—hematologic cancer	6.94e-06	8.55e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTM1—hematologic cancer	6.94e-06	8.55e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CB—hematologic cancer	6.92e-06	8.52e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KRAS—hematologic cancer	6.54e-06	8.06e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—KRAS—hematologic cancer	6.47e-06	7.96e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	6.28e-06	7.73e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CA—hematologic cancer	6.27e-06	7.73e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTP1—hematologic cancer	6.19e-06	7.62e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—MTHFR—hematologic cancer	6.14e-06	7.56e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CA—hematologic cancer	6.01e-06	7.4e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	5.98e-06	7.37e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTEN—hematologic cancer	5.98e-06	7.36e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CA—hematologic cancer	5.94e-06	7.32e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCB1—hematologic cancer	5.86e-06	7.21e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TP53—hematologic cancer	5.82e-06	7.16e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TP53—hematologic cancer	5.75e-06	7.08e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—EP300—hematologic cancer	5.7e-06	7.02e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTM1—hematologic cancer	5.68e-06	7e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NCOR1—hematologic cancer	5.68e-06	7e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HRAS—hematologic cancer	5.56e-06	6.85e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—HRAS—hematologic cancer	5.5e-06	6.77e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	5.41e-06	6.66e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6—hematologic cancer	5.32e-06	6.56e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CG—hematologic cancer	5.16e-06	6.35e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AKT1—hematologic cancer	5.13e-06	6.31e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MTHFR—hematologic cancer	5.02e-06	6.19e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT1—hematologic cancer	4.91e-06	6.05e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT1—hematologic cancer	4.85e-06	5.98e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CREBBP—hematologic cancer	4.78e-06	5.89e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CD—hematologic cancer	4.53e-06	5.58e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.43e-06	5.45e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3R1—hematologic cancer	4.28e-06	5.27e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CG—hematologic cancer	4.22e-06	5.2e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CA—hematologic cancer	4.22e-06	5.19e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CB—hematologic cancer	3.95e-06	4.87e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CREBBP—hematologic cancer	3.91e-06	4.82e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CD—hematologic cancer	3.71e-06	4.57e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALB—hematologic cancer	3.66e-06	4.51e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3R1—hematologic cancer	3.5e-06	4.31e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AKT1—hematologic cancer	3.44e-06	4.24e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTEN—hematologic cancer	3.41e-06	4.2e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—EP300—hematologic cancer	3.26e-06	4.01e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CB—hematologic cancer	3.23e-06	3.98e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTEN—hematologic cancer	2.79e-06	3.44e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—EP300—hematologic cancer	2.67e-06	3.28e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CA—hematologic cancer	2.41e-06	2.97e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CA—hematologic cancer	1.97e-06	2.43e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKT1—hematologic cancer	1.97e-06	2.42e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKT1—hematologic cancer	1.61e-06	1.98e-05	CbGpPWpGaD
